Integer Holdings Corporation reports news as a medical device contract development and manufacturing organization serving cardio and vascular, neuromodulation, and cardiac rhythm management markets. Company updates commonly cover sales trends, organic growth, product-line performance, adjusted earnings measures, debt and leverage, and outlook commentary tied to customer programs and new product activity.
Integer news also includes governance and capital-allocation developments, including board composition, shareholder engagement, share repurchase authorization, investor conference participation, and broader strategy updates. The company’s public identity includes the Greatbatch Medical and Lake Region Medical brands and engineering and manufacturing work for medical device customers.
Integer Holdings (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), has announced its participation in two upcoming investor conferences in March 2025.
President and CEO Joseph Dziedzic will present at the Raymond James & Associates' 46th Annual Institutional Investor Conference on March 5, 2025, at 11:00 a.m. ET in Orlando, Florida. Additionally, he will participate in a virtual fireside chat at the KeyBanc Capital Markets Healthcare Forum on March 19, 2025, at 9:45 a.m. ET.
Both presentations will be available via live webcast in the 'News & Events' section of Integer's Investor Relations website at investor.integer.net.
Integer Holdings has acquired Precision Coating from Katahdin Industries, , with the transaction closing on January 7, 2025. Precision Coating is a specialized provider of surface functionality enhancement services for patient-critical products in the Medtech industry.
Since 2006, the company has expanded through five strategic acquisitions: CHN Metal Finishing (2008), Medi-Solve (2008), Boyd Coatings Research (2015), N2 Biomedical (2021), and Providence Texture (2023). The company operates from four North American locations and one in Costa Rica.
Precision Coating's key offerings include GlideLine™ fluoropolymer coatings for medical devices, MICRALOX® patented anodic coatings for reusable medical instruments, and IonGuard® ion treatment for implants. The company has achieved nearly ten-fold growth through investments in data systems, automation, materials development, and international expansion.
Integer Holdings (NYSE: ITGR) will exhibit at MD&M West 2025 from February 4-6 at the Anaheim Convention Center, showcasing their medical device manufacturing capabilities at booth #1439. The company will demonstrate their expertise in cardio and vascular solutions, cardiac rhythm management, and neuromodulation products, including their global rapid prototyping services with two-week turnarounds.
A significant highlight is Integer's recent acquisition of Precision Coating for $152 million on January 7, 2025. This strategic move enhances Integer's capabilities with specialized surface coating technologies, including fluoropolymer, anodic coatings, ion treatment solutions, and laser processing. The acquisition aligns with Integer's tuck-in strategy and expands their service offerings to better serve customer needs.
The company will provide more details about the Precision Coating acquisition during their Q4 and full-year 2024 earnings call scheduled for February 20, 2025.
Integer Holdings (NYSE: ITGR), a leading medical device contract development and manufacturing organization, will showcase its innovations at the North American Neuromodulation Society (NANS) Annual Meeting from January 30 to February 1, 2025, in Orlando, Florida. At booth #213, Integer will present its latest advancements in neuromodulation and miniaturized active implantable medical devices (AIMDs).
The company will highlight its Xcellion® Gen 3 Fast Charge (FC) Lithium Ion implantable battery technology, which offers industry-leading battery runtime and can fully recharge in as little as 30 minutes. Integer aims to demonstrate its capabilities as a strategic partner for OEMs, focusing on accelerating and de-risking the path to market for novel implantable medical devices through their expertise in critical implantable technologies.
Integer Holdings (NYSE:ITGR) has announced its schedule for the release of fourth quarter and full year 2024 financial and operational results. The company will disclose the results on Thursday, February 20, 2025, at 7 a.m. Central Time (8 a.m. Eastern Time). Following the release, Integer's management team will host a webcast at 8 a.m. Central Time (9 a.m. Eastern Time) to discuss the results.
Integer Holdings (NYSE: ITGR) has announced that holders of its 2.125% Convertible Senior Notes due 2028 can convert their notes from January 1, 2025, through March 31, 2025. The conversion opportunity arose because the company's stock price exceeded 130% of the conversion price for at least 20 trading days within a 30-day trading period ending December 31, 2024.
The notes are convertible at a rate of 11.4681 shares of common stock per $1,000 principal amount, equivalent to a conversion price of approximately $87.20 per share. Upon conversion, holders will receive cash up to the principal amount, and either cash, shares, or a combination thereof for any remaining conversion value, at Integer's discretion.
Integer Holdings (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The event will take place from December 3-5, 2024, in New York City. President and CEO Joseph Dziedzic will deliver a presentation on Tuesday, December 3, 2024, at 10:30 a.m. EST. The presentation will be available through a live webcast, accessible via the Investor Relations section of Integer's website under 'News & Events' at investor.integer.net.
Integer Holdings (NYSE: ITGR) has completed the sale of its Electrochem business to Ultralife for $50 million in cash. The company will use the proceeds to reduce its outstanding debt. This divestiture transforms Integer into a pure-play medical technology company, focusing exclusively on its medical device contract development and manufacturing operations (CDMO). The strategic move aims to enable Integer to deploy additional capital in high-growth medtech markets.
Integer Holdings (NYSE: ITGR) announced key leadership changes effective Q1 2025. Payman Khales, current President of Cardio & Vascular, will become Chief Operating Officer, overseeing both product categories along with Global Operations and Manufacturing Strategy. Andrew Senn will succeed Khales as President of Cardio & Vascular. Under Khales' leadership since 2018, the Cardio & Vascular business achieved above-market growth. Senn brings 18 years of experience at Integer and extensive industry knowledge from various leadership roles.
Integer Holdings (NYSE:ITGR) reported strong Q3 2024 results with sales increasing 9% to $431 million, including 4% organic growth. GAAP income from continuing operations rose 29% to $36 million, while non-GAAP adjusted net income grew 14% to $50 million. The company raised its 2024 outlook, expecting sales growth of 10-11% with organic growth of 7-8%. The planned sale of Electrochem business for $50 million remains on track. Year-to-date sales increased 10% to $1.267 billion, with adjusted EBITDA up 22% to $266 million. Total debt stood at $1.079 billion with a leverage ratio of 3.0x adjusted EBITDA.